SLC5A2 and heart failure: The SOLOIST-WHF trial provided compelling evidence for the initiation of SGLT2 inhibitors in patients hospitalized with worsening heart failure, supporting the concept that these medications should be started during hospitalization rather than waiting for outpatient initiation.